ArticleFrontiers in oncology2025

Expression of aberrant markers in monitoring of measurable residual disease in B-cell precursor acute lymphoblastic leukemia patients during remission-inducing therapy phase.

Ł Słota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.